(NU/1433-37) NewCo: The Provision of Business Consultancy to Assist Commercialisation of University Research.
What the buyer wrote
Cancer and neurodegenerative diseases represent major unmet medical needs. It is estimated that approximately 20% of oncogenes are transcription factors (TFs) and many are critical for carcinogenesis. The global Cancer Drugs market was valued at US$92Bn in 2019 and is expected to reach US$124Bn by the end of 2026. The global neurodegenerative diseases drugs market size was valued at US$35.5Bn Million in 2018 and is projected to reach US$63Bn by the end of 2026. Specifically, we plan to target three cancer related TFs, (ATF4 CREB, and ID1) which are implicated in a range of cancer types that include glioma, breast cancer, acute myeloid leukaemia, and the aggregation of a-synuclein and amyloid…
Bid for this and lost? There is a short window in which the decision can be questioned.
Awarded to
Details
- What the buyer calls it
- (NU/1433-37) NewCo: The Provision of Business Consultancy to Assist Commercialisation of University Research.
- How they are buying
- Advertised, shortlist firstSuppliers applied to be considered, and the buyer picked who went on to bid.
- Type
- services
- Dynamic market
- Yes: you can apply to join at any time. How these work
- Where
- in the North East
- Kind of work
- Interpreting and translation
Who the buyer named
Natalie Morton was the named contact on this notice.